ArticleJournal of medical virology2025
IgG and IgM Seroreactivity Against Natural HPV16 Infection and HLA-DRB1 and -DQB1 Polymorphism.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Little is known about the factors associated with the natural humoral immune response against human papillomavirus (HPV) infection. The association between HLA-DRB1 and -DQB1 polymorphism and (1) HPV16 DNA detection, (2) naturally developed humoral immune response (IgG and IgM) against HPV16 L1 and L2 capsid proteins, and (3) type of HPV16 infection (transient or persistent) was investigated. Data from 943 women participating in the Ludwig-McGill cohort study was analyzed. HLA-DRB1 and HLA-DQB1 genotyping was done by PCR-based methods. HPV DNA was assessed every 4 months during the first year of follow-up, and HPV16 IgG and IgM antibody measurements were performed by ELISA in serum samples from the first and/or second visits. Associations were estimated by adjusted logistic regression models. HLA-DRB1*03:02 was associated with HPV16 DNA positivity (OR = 2.49, 95% CI: 1.11-5.60). HLA-DRB1*13:01 and HLA-DQB1*04:02 were associated with low levels of HPV16 IgG antibodies (OR = 0.44, 95% CI:0.23-0.87; OR = 0.10, 95% CI: 0.02-0.55, respectively). Neither IgM HPV16 antibodies nor the type of HPV16 infection (transient or persistent) were associated with HLA-DRB1 or -DQB1 variants. HLA-DRB1 and -DQB1 polymorphism might be associated with different levels of IgG against HPV16 infection, but IgM production and the type of infection seem to occur independently of these variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.